Interpretation of “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（2020 Edition） ”

doi:10.14009/j.issn.1672-2124.2020.05.001

您当前的位置：

首页 >

文章列表页 >

Interpretation of “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（2020 Edition） ”

更新时间：2022-10-08

- Interpretation of “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（2020 Edition） ”
- Vol. 20, Issue 5, Pages: 513-517(2020)
- 作者机构：
  
  1. 中国药理学会
  2. 中日友好医院
  3. 中国药理学会中日友好医院
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.05.001
  CLC： R979.1
- Published：2020，
扫描看全文
[1].《抗肿瘤生物类似药治疗药物监测药学专家共识(2020版)》解读[J].中国医院用药评价与分析,2020,20(05):513-517+520.

Interpretation of “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（2020 Edition） ”. [J]. 20(5):513-517(2020)
[1].《抗肿瘤生物类似药治疗药物监测药学专家共识(2020版)》解读[J].中国医院用药评价与分析,2020,20(05):513-517+520. DOI： 10.14009/j.issn.1672-2124.2020.05.001.

Interpretation of “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（2020 Edition） ”. [J]. 20(5):513-517(2020) DOI： 10.14009/j.issn.1672-2124.2020.05.001.

摘要

针对抗肿瘤生物类似药（antitumor biosimilars

At Bs）的临床使用问题

利用治疗药物监测（therapeutic drug monitoring

TDM）技术有助于指导和规范合理用药

中国药理学会和中日友好医院共同发起并制定了《抗肿瘤生物类似药治疗药物监测药学专家共识（2020版）》。该共识共计8个临床问题17条推荐意见

阐明了临床治疗中对AtBs进行TDM的必要性、个体化监测方案要点、技术方法和临床药师参与环节等

指导药师发挥主动性

利用TDM向医师提供切实的药学技术支撑

保证患者最大程度的获益。

Abstract

In response to the problems existing in the clinical use of antitumor biosimilars（AtBs）

the use of therapeutic drug monitoring（TDM） technology can help to guide and standardize the rational use of At Bs

the Chinese Pharmacological Society and China-Japan Friendship Hospital jointly initiated and formed"Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（2020 Edition） ". The consensus focuses on 8 clinical problems and makes 17 recommendations

which clarifies the necessity of TDM for At Bs in clinical treatment

key points of individualized monitoring program

technical methods and participation of clinical pharmacists

and guides pharmacists to provide practical pharmaceutical technical support to clinicians by TDM

so as to ensure the maximum benefits for patients.

关键词

抗肿瘤生物类似药治疗药物监测药学专家共识

Keywords

Antitumor biosimilarsTherapeutic drug monitoringPharmacy expert consensus

references

查看原文

Views

566

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Questionnaire Survey of Recommendations on “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（ 2020 Edition） ”

Progress of Therapeutic Drug Monitoring of Biologic Agents for Rheumatic and Immunological Diseases

Blood Concentration Monitoring of Digoxin in A Hospital and Its Influencing Factors

Effect of Different Preservation Conditions on Monitoring the Blood Concentration of Cyclosporine by Chemiluminescence Microparticle Immunoassay

Therapeutic Drug Monitoring and Influencing Factors of Voriconazole in Patients with Acquired Immunodeficiency Syndrome Complicated with Fungal Infection

Related Author

LI Bo

QIN Wangjun

LI Shu

ZHANG Xianglin

CHEN Wenqian

ZHANG Xiaojian

YANG Jing

QIN Zhiying

Related Institution

Dept. of Pharmacy, China-Japan Friendship Hospital

Henan Engineering Research Center for Application ＆ Translation of Precision Clinical Pharmacy

Henan Key Laboratory of Precision Clinical Pharmacy

Dept. of Pharmacy, the First Affiliated Hospital of Zhengzhou University

Dept.of Pharmacy, Air Force General Hospital of PLA

⁰